Kjøbli Eirik, Haug Erik Skaaheim, Salvesen Øyvind, Arstad Christian, Bergesen Anne Kvaale, Brennhovd Bjørn, Carlsen Birgitte, Gharib-Alhaug Bita, Gudbrandsdottir Gigja, Juliebø-Jones Patrick, Haugland Julie Nøss, Karlsvik Ann-Karoline, Larsen Magnus, Lilleaasen Gunder Magne, Mûller Stig, Plathan May Lisbeth, Roaldsen Marius, Roth Ingunn, Schwenke Bernd Lukas Luca, Wahlqvist Rolf, Wessel Nicolai, Wibe Arne, Beisland Christian
Department of Urology, St. Olav's University Hospital, 7030 Trondheim, Norway.
Department of Urology, Vestfold Hospital Trust, 3103 Tønsberg, Norway.
Cancers (Basel). 2025 Jan 25;17(3):404. doi: 10.3390/cancers17030404.
: Pelvic lymph node dissection during standard radical cystectomy (stdRC) for muscle invasive bladder cancer is performed as separate templates. In the modernized en bloc radical cystectomy (mEbRC), the bladder is removed together with all its associated lymphatic tissue as one specimen. Our aim was to evaluate the oncological and surgical outcomes of mEbRC with a propensity-matched national cohort of stdRC cases. : 935 patients (mEbRC: 214 and stdRC: 721) were eligible for analysis, and 1:2 propensity score matching was performed regressing mEbRC treatment on the variables age, gender, neoadjuvant chemotherapy, Charlson Comorbidity Index, lymph node metastases at final pathology, carcinoma in situ, and pT-stage. The primary outcome was recurrence-free survival (RFS). Secondary endpoints were overall survival (OS) and cancer-specific survival (CSS), survival for female patients. and perioperative measures. : There were no significant differences between the groups regarding complications, 30-day readmission rates, and 30- and 90-day mortality rates. In the propensity score matched groups, the 5-year RFS was 83% in the mEbRC group vs. 67% in the stdRC group ( < 0.001), the CSS was 89% and 78% ( ≤ 0.001), and OS 81% vs. 68% ( < 0.001) in the same groups, respectively. The results were confirmed by Cox regression analyses with hazard ratios ranging from 0.41 to 0.50 and -values ≤ 0.001, favoring mEbRC. The 5-year OS for female patients was 86% for mEbRC and 60% for stdRC ( = 0.022). : Performing mEbRC over stdRC might yield significantly better oncological outcomes, with equal survival rates for both genders.
在对肌层浸润性膀胱癌进行标准根治性膀胱切除术(stdRC)时,盆腔淋巴结清扫是按照不同的模板进行的。在现代化的整块根治性膀胱切除术(mEbRC)中,膀胱与其所有相关淋巴组织作为一个标本一起被切除。我们的目的是通过倾向评分匹配的全国性stdRC病例队列来评估mEbRC的肿瘤学和手术结果。935例患者(mEbRC组:214例,stdRC组:721例)符合分析条件,并进行了1:2倾向评分匹配,将mEbRC治疗结果与年龄、性别、新辅助化疗、Charlson合并症指数、最终病理检查时的淋巴结转移情况、原位癌以及pT分期等变量进行回归分析。主要结局是无复发生存期(RFS)。次要终点包括总生存期(OS)、癌症特异性生存期(CSS)、女性患者生存期以及围手术期指标。两组在并发症、30天再入院率以及30天和90天死亡率方面没有显著差异。在倾向评分匹配组中,mEbRC组的5年RFS为83%,而stdRC组为67%(P<0.001);相同组别的CSS分别为89%和78%(P≤0.001),OS分别为81%和68%(P<0.001)。Cox回归分析结果证实了这些结果,风险比范围为0.41至0.50,P值≤0.001,支持mEbRC。mEbRC组女性患者的5年OS为86%,stdRC组为60%(P = 0.022)。与stdRC相比,进行mEbRC可能会产生显著更好的肿瘤学结果,且两性生存率相同。